Brief: Todos Medical And NLC Pharma Announce Interim Data For Nlc-V-01 Phase 2 Clinical Trial
27/01/2022 14:25
Jan 27 (Reuters) - Todos Medical Ltd TOMDF.PK :
* TODOS MEDICAL AND NLC PHARMA ANNOUNCE PRIMARY AND
SECONDARY
ENDPOINTS MET IN NLC-V-01 PHASE 2 CLINICAL TRIAL OF ORAL
ANTIVIRAL 3CL PROTEASE INHIBITOR TOLLOVIR™ IN TREATMENT OF
HOSPITALIZED COVID-19 PATIENTS
* TODOS MEDICAL LTD - HAS NOW FORMALLY CLOSED THE PHASE 2
CLINICAL
TRIAL DUE TO POSITIVE INTERIM EFFICACY DATA
* TODOS MEDICAL LTD - IN THE PROCESS OF FINE TUNING PROPOSED
PHASE
2/3 CLINICAL STUDY PROTOCOL FOR HOSPITALIZED COVID-19 PATIENTS
Source text for Eikon: ID:nGNX3hg0Hs
Further company coverage: TOMDF.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Todos Medical
See all newsBrief: Todos Medical Enters Into Exclusive Worldwide Automated Retail Supply Agreement With Smart Automated Retail Network
Brief: Todos Medical Clia/Cap Lab Provista Submits Emergency Use Authorization Application For Monkeypox Pcr Test To Us FDA
Brief: Todos Medical Provides Corporate Update
Brief: Todos Medical Enters Into $50 Mln Contract To Supply Tollovid, CBD Products To Retail Distributor Company Nerd Hemp
Brief: Todos Medical Establishes Botanical Supplement Manufacturing Capabilities